Patient Power interview with Dr. Ansell from Mayo Clinic.
Will There Be a Cure For Waldenstrom Macroglobulinemia?
Patient Power interviews with Dr. Treon from DFCI
Are We Close to a Cure for Waldenstrom Macroglobulinemia?
How Are… Continue reading
BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemia, according to Steven P. Treon, MD, PhD, who added that with 4 agents under examination in the space, selection will depend… Continue reading
CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its New Drug Submission (NDS) for BRUKINSA® (zanubrutinib) for the treatment of patients with Waldenström’s… Continue reading
Over the last 20 years the WMFC members have generously supported a tremendous amount of research. Some of it has been groundbreaking, helping change the lives of Canadian WMers for the better. As an organization, the WMFC is now focusing… Continue reading
Dr. Zachary Hunter recently spoke at an Atlantic Support Group Zoom Meeting. Click on the link below to view his presentation entitled “What is New in Waldenstrom’s Macroglobulinemia Research?” His talk is followed by a question and answer session.
Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.
-June 14/20 Published here: onclive.com-
Meletios A. Dimopoulos, MD, professor and chairman of the Department of Clinical Therapeutics at… Continue reading
In the first head-to-head comparison of Bruton tyrosine kinase (BTK) inhibitors, zanubrutinib demonstrated statistically significant and clinically meaningful advantages in safety and tolerability in patients with Waldenström macroglobulinemia (WM) compared with ibrutinib. Although zanubrutinib yielded a numerically higher response rate… Continue reading
In this video, an international panel of experts sat down with Oncology Learning Network to discuss the 3 Bruton’s tyrosine kinase (BTK) inhibitors active in the treatment of Waldenström macroglobulinemia (WM): ibrutinib, acalabrutinib, and zanubrutinib.
This discussion is moderated by… Continue reading